CCHIO Leadership Dialogue | Prof. Gang Zhu: When Robotics Meets Holography — A Leap Toward Precision in Urologic Oncology Surgery

CCHIO Leadership Dialogue | Prof. Gang Zhu: When Robotics Meets Holography — A Leap Toward Precision in Urologic Oncology Surgery

2025.12.14
From November 6–9, 2025, the China Congress of Holistic Integrative Oncology (CCHIO 2025) took place in Kunming. The conference was hosted by the China Anti-Cancer Association (CACA) and the Tengchong Scientist Forum Organizing Committee, co-organized by the World Association of Integrative Oncology (WAIO) and the China Academy of Integrative Medicine, and jointly undertaken by Yunnan Cancer Hospital, Kunming Medical University, and the Yunnan Anti-Cancer Association. As urologic cancers remain among the world’s most common malignancies, advances in this field garnered significant attention at CCHIO 2025. Oncology Frontier – Urology Frontier invited Prof. Gang Zhu, Chair of the CACA Committee on Integrative Rehabilitation for Genitourinary Tumors and Professor at Beijing United Family Hospital and Clinics, to discuss the clinical value of holographic imaging in robotic surgery, its integration with systemic therapies, and his perspectives on training young surgeons.
“Six Fewer Needles*!” — Peking University First Hospital Reports Breakthrough in Precision Prostate Biopsy, Published in The Lancet Sub-Journal

“Six Fewer Needles*!” — Peking University First Hospital Reports Breakthrough in Precision Prostate Biopsy, Published in The Lancet Sub-Journal

2025.12.14
On November 14, a research team led by Prof. Kan Gong and Associate Chief Physician Yi Liu from the Department of Urology, Peking University First Hospital and the Institute of Urology, Peking University, published a major advancement in precision prostate biopsy in eClinicalMedicine, a sub-journal of The Lancet.
Junhua Zheng/ Wei Zhai Team Develops Multimodal AI Model for Kidney Cancer, Published in a Nature Sub-Journal

Junhua Zheng/ Wei Zhai Team Develops Multimodal AI Model for Kidney Cancer, Published in a Nature Sub-Journal

2025.12.14
Recently, the urology team led by Prof. Junhua Zheng and Researcher Wei Zhai from the Department of Urology, Renji Hospital, Shanghai Jiao Tong University School ofkk Medicine, together with multiple collaborating centers, achieved a major breakthrough in precision prognosis of kidney cancer. Their multimodal prediction of recurrence score (MPRS) model was successfully published in npj Digital Medicine, a leading global digital medicine journal under the Nature portfolio. This model provides crucial support for recurrence-risk assessment and individualized treatment in patients with clear cell renal cell carcinoma (ccRCC).
CCHIO Leadership Dialogue | Prof. Changling Li: From “Following” to “Leading” — China’s Global Breakthroughs and New Directions in Precision Urologic

CCHIO Leadership Dialogue | Prof. Changling Li: From “Following” to “Leading” — China’s Global Breakthroughs and New Directions in Precision Urologic

2025.12.14
From November 6–9, 2025, the China Congress of Holistic Integrative Oncology (CCHIO 2025) was held in Kunming. The conference was hosted by the China Anti-Cancer Association (CACA) and the Tengchong Scientist Forum Organizing Committee, co-organized by the World Association of Integrative Oncology (WAIO) and the China Academy of Integrative Medicine, and jointly undertaken by Yunnan Cancer Hospital, Kunming Medical University, and the Yunnan Anti-Cancer Association. As urologic cancers remain among the most common malignancies worldwide, advances in this field drew substantial attention at CCHIO 2025. Oncolgy  Frontier– Urology Frontier invited Prof. Changling Li, Executive Chair of the CACA Committee on Integrative Urologic Oncology and Chair of the CACA Urologic Oncology Committee, to share insights on integrative oncology, China’s recent breakthroughs, and future directions.
Professors Huafeng Wang and Mikkael Sekeres Discuss ASH Guidelines Update for Elderly AML Patients and Its Implications for Treatment Pathways in China

Professors Huafeng Wang and Mikkael Sekeres Discuss ASH Guidelines Update for Elderly AML Patients and Its Implications for Treatment Pathways in China

2025.12.13
On December 7th, local time, the highly anticipated session on the "Updated ASH Clinical Practice Guidelines on Acute Myeloid Leukemia (AML) in Older Adults" was successfully held at the American Society of Hematology (ASH) Annual Meeting. This session was chaired by Professor Mikkael Sekeres, the lead expert of the ASH guidelines and Director of the Department of Hematology at Sylvester Comprehensive Cancer Center. To gain deeper insights into the key points of the guideline update and the emerging trends it reflects, Oncology Frontier- Hematology Frontier invited Professor Huafeng Wang from Zhejiang University School of Medicine’s First Affiliated Hospital to engage in a deep dialogue with Professor Sekeres.